Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

PepGen Inc. - Common Stock (NQ:PEPG)

5.410 +0.210 (+4.04%)
Streaming Delayed Price Updated: 10:29 AM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PepGen Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Over $37M Bet On This Industrial Stock? Check Out These 4 Stocks Insiders Are Buying ↗
Although U.S. stocks closed sharply lower on Tuesday, there were a few notable insider trades. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen: Q3 Earnings Insights ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for PepGen ↗
 
Via Benzinga
News headline image
PepGen: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
PepGen soars on Sarepta Therapeutics’ Duchenne drug phase 2 data
PepGen stock is moving higher on expectations of positive Phase 2 clinical trial results for its Duchenne muscular dystrophy (DMD) gene therapy 
Via MarketBeat
News headline image
Top 4 Health Care Stocks That May Crash This Quarter ↗
As of Feb. 2, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Mary Beth DeLena Joins PepGen as General Counsel and Secretary
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1
The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to PGN-EDODM1 for the treatment of Myotonic Dystrophy Type 1 (DM1) 
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company’s Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1
From PepGen Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Why American Software Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Advanced Health Intelligence Ltd. (NASDAQ: AHI) shares jumped 144.5% to $0.7827. 
Via Benzinga
News headline image
SAIC, HealthEquity And 3 Stocks To Watch Heading Into Monday ↗
With U.S. stock futures trading mixed this morning on Monday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
News headline image
PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen Reports First Quarter 2023 Financial Results and Recent Corporate Developments
From PepGen Inc.
Via GlobeNewswire
News headline image
Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 59.6% to $0.2513. Crown Electrokinetics said it has entered into an agreement with a leading infrastructure solutions provider. 
Via Benzinga
News headline image
BioNTech, Coinbase Global, Pharming Group And Other Big Stocks Moving Lower On Monday ↗
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.